After a two-month takeover battle over a U.S. obesity drug developer between U.S. company Pfizer and Denmark’s Novo Nordisk, the contest ended in victory for Pfizer, which had initially agreed to ...
New! Sign up for our free email newsletter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback